Cite
HARVARD Citation
Dignass, A. et al. (n.d.). P431 A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistence. Journal of Crohn's and colitis. pp. i558-i559. [Online].